Global Anti-Infective Agents Market Size study, by Type/Drug Class (Antibacterials, Antivirals, Antifungals), by Route of Administration (Topical, Oral, IV, Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Specialty Pharmacies, E-

Global Anti-Infective Agents Market Size study, by Type/Drug Class (Antibacterials, Antivirals, Antifungals), by Route of Administration (Topical, Oral, IV, Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Specialty Pharmacies, E-Commerce, Others) and Regional Forecasts 2022-2032

The Global Anti-Infective Agents market was valued at approximately USD 136.9 billion in 2023 and is projected to experience a modest growth rate with a CAGR of 1.2% over the forecast period from 2024 to 2032. Anti-infective agents, encompassing antibiotics, antivirals, antifungals, and antiparasitics, play a pivotal role in both human and veterinary medicine by preventing and treating infections caused by various microorganisms. These agents are critical in the management of diseases such as bacterial pneumonia, HIV, fungal infections, and malaria, and are indispensable in surgical procedures and for immunocompromised patients to prevent infections. Beyond healthcare, anti-infective agents are utilized in agriculture to protect plants from pathogens and in sanitation products to maintain hygiene.
The market's growth is significantly driven by the rising prevalence of infectious diseases, including the COVID-19 pandemic, tuberculosis, and malaria, which necessitate effective treatments to manage outbreaks and prevent pandemics. Furthermore, the escalating issue of antibiotic resistance underscores the urgent need for innovative anti-infective agents. Pharmaceutical companies and research institutions are investing heavily in developing new drugs to combat resistant strains, supported by global health initiatives targeting antibiotic resistance as a critical public health threat. Advancements in drug development technologies, such as genomics, proteomics, and bioinformatics, have facilitated the creation of novel anti-infective agents with improved efficacy and reduced side effects. These technological strides are attracting significant investment and fostering market expansion. Also, Emerging markets, particularly in Asia, Africa, and Latin America, present substantial growth opportunities due to increasing healthcare expenditure and improving access to healthcare services. Pharmaceutical companies are expanding their presence in these regions to capitalize on the growing demand for healthcare solutions. Additionally, innovations in biotechnology, including the development of biologics and biosimilars, are opening new avenues for the anti-infective agents market, offering more effective treatments and diversification opportunities. However, the market faces challenges such as stringent regulatory requirements, which can delay the introduction of new products. The complex and time-consuming approval process, coupled with the high cost of compliance, can be a significant barrier, particularly for smaller companies.
North America dominated the market in 2023, accounting for the largest share of 37.0% of the overall revenue. The region's sophisticated healthcare infrastructure, increasing awareness among healthcare professionals, and strong government emphasis on public health initiatives drive market growth. The Asia Pacific region is projected to expand at the fastest growth rate of 3.7% during the forecast period, driven by the presence of generic companies, rising economic stability, increasing disposable income levels, and a growing aging population susceptible to infections.
Major market players included in this report are:
Pfizer Inc.
Abbott
Gilead Sciences, Inc.
Bristol-Myers Squibb Company
Merck & Co., Inc.
Sandoz International GmbH
B. Braun SE
Xellia Pharmaceuticals
Mankind Pharma
Bayer AG
AstraZeneca
Boehringer Ingelheim International GmbH
GlaxoSmithKline plc
Novartis AG
Johnson & Johnson
The detailed segments and sub-segment of the market are explained below:
By Type/Drug Class:
• Antibacterials
• Antivirals
• Antifungals
By Route of Administration:
• Topical
• Oral
• IV
• Others
By Distribution Channel:
• Hospital Pharmacies
• Retail Pharmacies
• Specialty Pharmacies
• E-Commerce
• Others
By Region:
North America
• U.S.
• Canada
Europe
• UK
• Germany
• France
• Spain
• Italy
• ROE
Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC
Latin America
• Brazil
• Mexico
• RoLA
Middle East & Africa
• Saudi Arabia
• South Africa
• RoMEA
Years considered for the study are as follows: Historical year – 2022 Base year – 2023 Forecast period – 2024 to 2032
Key Takeaways:
• Market Estimates & Forecast for 10 years from 2022 to 2032.
• Annualized revenues and regional level analysis for each market segment.
• Detailed analysis of geographical landscape with Country level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of competitive structure of the market.
• Demand side and supply side analysis of the market.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.